A lyophilized gel-phase liposomal composition is provided which comprises more than one therapeutic and/or diagnostic agent, substantially no internal cryoprotectant, gel-phase liposomes with gel-to-liquid crystalline transition temperatures (Tc) that are at least 25°C, wherein the liposomes are 20 mol% or less cholesterol liposomes that are stabilized with at least 1% of a phosphatidylglycerol (PG) and/or a phosphoinositol (PI), and cryoprotectant external to said liposomes. The lyophilized gel-phase liposomal composition and said composition reconstituted in a suitable pharmaceutical carrier are provided for use in therapy.
